365 related articles for article (PubMed ID: 33291506)
1. Prospects for Using Expression Patterns of Paramyxovirus Receptors as Biomarkers for Oncolytic Virotherapy.
Matveeva OV; Shabalina SA
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33291506
[TBL] [Abstract][Full Text] [Related]
2. Measles to the Rescue: A Review of Oncolytic Measles Virus.
Aref S; Bailey K; Fielding A
Viruses; 2016 Oct; 8(10):. PubMed ID: 27782084
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of Oncolysis by Paramyxovirus Sendai.
Matveeva OV; Kochneva GV; Netesov SV; Onikienko SB; Chumakov PM
Acta Naturae; 2015; 7(2):6-16. PubMed ID: 26085940
[TBL] [Abstract][Full Text] [Related]
4. [Oncolytic Paramyxoviruses: Mechanism of Action, Preclinical and Clinical Studies].
Matveeva OV; Kochneva GV; Zainutdinov SS; Ilyinskaya GV; Chumakov PM
Mol Biol (Mosk); 2018; 52(3):360-379. PubMed ID: 29989571
[TBL] [Abstract][Full Text] [Related]
5. Novel oncolytic viral therapies in patients with thoracic malignancies.
Ahmad Z; Kratzke RA
Oncolytic Virother; 2017; 6():1-9. PubMed ID: 28053943
[TBL] [Abstract][Full Text] [Related]
6. Oncolysis by paramyxoviruses: preclinical and clinical studies.
Matveeva OV; Guo ZS; Senin VM; Senina AV; Shabalina SA; Chumakov PM
Mol Ther Oncolytics; 2015; 2():15017-. PubMed ID: 26640815
[TBL] [Abstract][Full Text] [Related]
7. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy.
Iankov ID; Blechacz B; Liu C; Schmeckpeper JD; Tarara JE; Federspiel MJ; Caplice N; Russell SJ
Mol Ther; 2007 Jan; 15(1):114-22. PubMed ID: 17164782
[TBL] [Abstract][Full Text] [Related]
8. Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells.
Petrovic B; Leoni V; Gatta V; Zaghini A; Vannini A; Campadelli-Fiume G
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263257
[TBL] [Abstract][Full Text] [Related]
9. A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells.
Leoni V; Gatta V; Casiraghi C; Nicosia A; Petrovic B; Campadelli-Fiume G
J Virol; 2017 May; 91(10):. PubMed ID: 28250120
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulation in Oncolytic Measles Virotherapy.
Dietz L; Engeland CE
Methods Mol Biol; 2020; 2058():111-126. PubMed ID: 31486034
[TBL] [Abstract][Full Text] [Related]
11. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.
Hasegawa K; Pham L; O'Connor MK; Federspiel MJ; Russell SJ; Peng KW
Clin Cancer Res; 2006 Mar; 12(6):1868-75. PubMed ID: 16551872
[TBL] [Abstract][Full Text] [Related]
12. Macrophage response to oncolytic paramyxoviruses potentiates virus-mediated tumor cell killing.
Tan DQ; Zhang L; Ohba K; Ye M; Ichiyama K; Yamamoto N
Eur J Immunol; 2016 Apr; 46(4):919-28. PubMed ID: 26763072
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic paramyxoviruses-induced autophagy; a prudent weapon for cancer therapy.
Keshavarz M; Solaymani-Mohammadi F; Miri SM; Ghaemi A
J Biomed Sci; 2019 Jun; 26(1):48. PubMed ID: 31217023
[TBL] [Abstract][Full Text] [Related]
14. Measles virus as an oncolytic vector platform.
Blechacz B; Russell SJ
Curr Gene Ther; 2008 Jun; 8(3):162-75. PubMed ID: 18537591
[TBL] [Abstract][Full Text] [Related]
15. Graphene oxide arms oncolytic measles virus for improved effectiveness of cancer therapy.
Xia M; Luo D; Dong J; Zheng M; Meng G; Wu J; Wei J
J Exp Clin Cancer Res; 2019 Sep; 38(1):408. PubMed ID: 31533779
[TBL] [Abstract][Full Text] [Related]
16. A mathematical model of oncolytic virotherapy with time delay.
Wang ZZ; Guo ZM; Smith H
Math Biosci Eng; 2019 Mar; 16(4):1836-1860. PubMed ID: 31137188
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic Measles Virus Encoding MicroRNA for Targeted RNA Interference.
Anker SC; Szczeponik MG; Dessila J; Dittus K; Engeland CE; Jäger D; Ungerechts G; Leber MF
Viruses; 2023 Jan; 15(2):. PubMed ID: 36851522
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic adenoviruses - selective retargeting to tumor cells.
Mathis JM; Stoff-Khalili MA; Curiel DT
Oncogene; 2005 Nov; 24(52):7775-91. PubMed ID: 16299537
[TBL] [Abstract][Full Text] [Related]
19. Starvation-Induced Differential Virotherapy Using an Oncolytic Measles Vaccine Virus.
Scheubeck G; Berchtold S; Smirnow I; Schenk A; Beil J; Lauer UM
Viruses; 2019 Jul; 11(7):. PubMed ID: 31284426
[TBL] [Abstract][Full Text] [Related]
20. DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety.
Friedrich K; Hanauer JR; Prüfer S; Münch RC; Völker I; Filippis C; Jost C; Hanschmann KM; Cattaneo R; Peng KW; Plückthun A; Buchholz CJ; Cichutek K; Mühlebach MD
Mol Ther; 2013 Apr; 21(4):849-59. PubMed ID: 23380817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
